Interim report
Page 1
October 31, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Dear Sir, Subject: Outcome of Board Meeting held on October 31, 2026 Ref: ISIN: INE837H01020 With reference to the notice of the Board Meeting dated October 23, 2026, we hereby inform that the Board of Directors at its Meeting held on October 31, 2026 (commenced at 10:45 a.m. and concluded at 11:35 a.m.) has inter alia, transacted the following business: Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026. Please find enclosed herewith the above mentioned Financial Results along with the Limited Review Report from the Statutory Auditors as Annexure – I. Analyzed the requests received from the promoter group members for their reclassification from promoter group category to public category shareholders, pursuant to Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The details of the promoter group members who had requested for reclassification along with the views of the Board on those requests is enclosed as Annexure – II. The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com This is for your information and for public at large. Thanking you, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head – Legal Encl.: As above Advanced enzymesWhere ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200,Fax: +91-22-2583 5159 Email:info@advancedenzymes.com, www.advancedenzymes.com Factory :Plot No. A-61/62, MIDC Malegaon, Tal. Sinnar, Dist. Nashik - 422 113. Maharashtra. India. Tel.: +91-99701 00750 / +91-2551-230 044, Fax: +91-2551-230 816
Page 2
Annexure-I MSK A & Associates LLP HO 602, Floor 6,Raheja Titanium Western Express Highway, Geetanjali Railway Colony, Ram Nagar, Goregaon (E) Mumbai 400063, INDIA Tel: +91 22 6974 0200 (Formerly known as M S K A & Associates) Chartered Accountants Independent Auditor’s Review Report on consolidated unaudited financial results of Advanced Enzyme Technologies Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,as amended To the Board of Directors of Advanced Enzyme Technologies Limited We have reviewed the accompanying Statement of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as ‘the Holding Company’), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the ‘Group’) and its share of the net loss after tax and total comprehensive loss of its associate for the quarter ended September 30, 2026 and the year to-date results for the period from April 01, 2026 to September 30, 2026 (‘the Statement’) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable. This Statement includes the results of the Holding Company and the following entities: 1. 2. 3. 4. Name of the EntitySr.No Relationship with the Holding Company 1 Advanced Bio-Agro Tech Limited Subsidiary 2 Advanced Enzytech Solutions Limited Wholly Owned Subsidiary 3 Advanced Enzymes USA, Inc. (‘AEU’) Wholly Owned Subsidiary Advanced Supplementary Technologies Corporation Wholly Owned Subsidiary of4 AEU Cal India Foods International (‘CAL’) Wholly Owned Subsidiary of5 AEU Registered Office: 602,Raheja Titanium,Western Express Highway, Goregaon (East),Mumbai-400063,Maharashtra,India Tel: +91 22 6974 0200 | LLPIN:ACT-3789 Ahmedabad I Bengaluru | Chandigarh | Chennai I Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata Pune www.mska.in
Page 3
MSK A fit Associates LLP(Formerly known as M S K A & Associates) Chartered Accountants Enzyme Innovation, Inc Wholly Owned Subsidiary of6 CAL 7 JC Biotech Private Limited (‘JCB’) Subsidiary 8 Scitech Specialities Private Limited Subsidiary 9 Advanced Enzymes Europe B.V. (‘AEEBV’) Wholly Owned Subsidiary Evoxx Technologies GmbH Wholly Owned Subsidiary of AEEBV10 11 Saiganesh Enzytech Solutions Private Limited Subsidiary Starya Labs Inc. Wholly Owned Subsidiary of12 AEU Advanced Nutrazyme Private Limited Wholly Owned Subsidiary (with effect from July 04, 2025)13 Raywatt Solar Enviro Private Limited Associate of JCB (with effect from August 10, 2026)14 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. We did not review the interim financial information of four subsidiaries included in the Statement, whose interim financial information (before consolidation adjustment) reflects total assets of Rs. 2,263.07 million as at September 30, 2026 and total revenues of Rs. 650.59 million and Rs. 1,252.39 million, total net profit after tax of Rs. 71.04 million and Rs. 95.94 million and total comprehensive income of Rs. 70.14 million and Rs. 95.07 million for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026 respectively, and cash outflows (net) of Rs. 11.13 million for the period from April 01, 2026 to September 30, 2026, as considered in the Statement. These interim financial information have been reviewed by the other auditors whose reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors. 7. One subsidiary is located outside India whose interim financial information has been prepared in accordance with the accounting principles generally accepted in their respective country and which has been reviewed by other auditor under generally accepted auditing standards applicable in their respective country. The Holding Company’s Management has converted the interim financial information of such subsidiary located outside India from accounting principles generally accepted in their respective country to accounting principles generally accepted in India. Registered Office: 602,Raheja Titanium, Western Express Highway, Goregaon (East),Mumbai-400063,Maharashtra,India Tel: +91 22 6974 0200 |LLPIN:ACT-3789 Bengaluru I Chandigarh I Chennai | Coimbatore | Goa | Gurugram | Hyderabad I Kochi | Kolkata | Mumbai I Pune www.mska.in
Page 4
MSK A 8t Associates LLP(Formerly known as M S K A & Associates) Chartered Accountants We have reviewed these conversion adjustments made by the Holding Company’s Management. Our conclusion on the Statement, in so far as it relates to the interim financial information of such subsidiary located outside India is based on the report of other auditor and the conversion adjustments prepared by the Management of the Holding Company and reviewed by us. Our conclusion is not modified in respect of the above matter. 8. The Statement includes the interim financial information of four subsidiaries which has not been reviewed by their auditors, whose interim financial information (before consolidation adjustment) reflects total assets of Rs. 1283.92 million as at September 30, 2026 and total revenue of Rs. 78.71 million and Rs. 155.87 million, total net profit after tax of Rs. 16.75 million and Rs. 15.87 million and total comprehensive income of Rs. 16.75 million and Rs. 15.87 million for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026 respectively, and cash inflows (net) of Rs. 6.90 million for the period from April 01, 2026 to September 30, 2026 as considered in the Statement. The Statement also includes the Group’s share of net loss after tax of Rs. 0.18 million and Rs. 0.18 million and total comprehensive loss of Rs. 0.18 million and Rs. 0.18 million for the quarter ended September 30, 2026 and for the period from August 10, 2026 to September 30, 2026, respectively, as considered in the Statement, in respect of associate, based on their interim financial information which has not been reviewed by their auditor are not subject to review. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial information certified by the management. For M S K A & Associates LLP (Formerly known as M S K A a Associates) Chartered Accountants ICAI Firm Registration No.105047W/W101187 Virendra Kanak Partner Membership No.: 110811 UDIN:24|IV&II Place:Mumbai Date: October 31, 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN:ACT-3789 Ahmedabad I Bengaluru I Chandigarh | Chennai I Coimbatore | Goa | Gurugram | Hyderabad I Kochi I Kolkata I Mumbai | Pune www.mska.in
Page 5
> Advanced Enzyme Technologies Limited CIN No :L24200 MH 1989 PLC 051018 Regd .Office and Corporate Office :Sun Magnetica ,5th Floor .Near LIC Service Road .Louiswadi .Thane -400604 .Maharashtra , hdia Tel No 91 -22 -41703220 ,Fax No .+91 -22 -25835159 Website :www advancedenzymes com ,Email Id sanjay @ advancedenzymes com Statement of unaudited consolidated financial results for the quarter and six months ended 30 September 2026 (f in million except per share data ) Six months ended Year ended Quarter ended Particulars 30 -Sep -25 Unaudited 30 Sep -26 Unaudited 30 -Sep -25 Unaudited 31 -Mar -26 Audited 30 -Sep -26 Unaudited 30 -Jun -26 Unaudited 4,062.21198.17 3,704 42 191 34 7,457 57 348 32 1,845.28102 84 2,145.0987.20 1,917.12110.97 Revenue from operations Other Income 12 4,260.38 3,895.76 7,805.89 2,028.09 1,948.12 2,232.29 Total Income (1+2) 3 Expenses(a) Cost of materials consumed (b) Purchases of stock -in-trade # (c) Changes in inventories of finished goods ,work -in -progress and stock -in-trade (d) Employee benefits expense (e) Finance costs (including exchange difference ) (f) Depreciation and amortisation expense (q) Other expenses 4 1,135.95 92712 1,943 12 545 02 487 42 590.93 0.00 0.13 0 1 2 0.01 0 00 000 (74.98 ) 849.9817.62207.75901 10 19 04 790 86 14 86 196 94 802 53 (13 61 ) 1.622 86 26 28 400 93 1 ,614 54 (48 14 ) 445 52 (41 75 ) 393 73 (26 84 ) 404 46 11 82 108.96455.27 5.80 7 22 98.79445 83 100 76 405 33 1,544.72 1,492.83 1,352.71 3,037.55 2,751.35 5,594.12 Total Expenses 1,222.83 2,211.77 535.26 595.41 1,144.41 687.57 Profit before exceptional item and tax (3-4) 5 (113 59 ) Exceptional item (charge /(credit ))(refer note vii & viii ) 6 1,222.83 1,144.41 2,325.36 687.57 535.26 595.41 Profit before tax (5-6) Tax expenseCurrent tax 78 352.24(27 01 ) 150 65 156 92 311 62 (18.94 ) 564 46 24 82 201 59 (25.73 ) (1 28 ) (8 84 ) Deferred tax charge /(credit ) Total tax expense 149.37 148.08 325.23 292.68 589.28 175.86 851.73 1,736.08 385.89 447.33 897.60 511.71 (0 18 ) Net profit for the period (7-8) Share of net (loss )in associate using equity method Group consolidated net profit (9-10 ) 9 (0.18 ) 10 447.33 897.42 851.73 1,736.08 385.89 511.53 11 Other comprehensive income A (i) Items that will not be reclassified to profit or loss Remeasurements of defined benefit liability /(asset ) (II)Income tax related to items that will not be reclassified to profit or loss B (i)Items that will be reclassified to profit or loss Exchange differences in translating financial statements of foreign operations (ii)Income tax related to items that will be reclassified to profit or loss Total Other comprehensive income 12 0 95 (1.17 ) 0 38 (1.19 ) 0.02 13.40(337 ) 0 29 0.30 (0.01 ) (0 27 ) (0 11 ) 143 03 (14.28 ) 311 39 128.75 349 51 938 08 (14.27 ) 312.07 127.87 349.79 948.11 142.14 1,201.51 653.67 371.62 759.40 1,025.29 2,684.19 Total comprehensive income (11 +12 ) 13 Net profit attributable to : Shareholders of the Company Non -controlling interest Other comprehensive income attributable to : Shareholders of the Company Non -controlling interest ff Total comprehensive income attributable to : Shareholders of the Company Non -controlling interest 12 370 93 14 96 853.9943.43 832 57 19.17 483 06 28 47 433.2614 07 1,687.1948 89 13 312 04 127 91 (0 04 ) 349 77 14218(0.04 ) (14 27 ) 947.42 0.00 003 0 01 069 14 1.182 .34 19.18 625.2428.43 356 66 14 96 745.3014 10 981 90 43.39 2,634 61 49.58 g - Paid -up Equity Share Capital (Face Value ? 2 each fully paid up ) 223.76 220.53 223.76 223.85 220.53 223.95 15 — y/ — Other equity 16 ,095 72 16 Earnings Per Share of f2each (not annualized ) (a) ? (Basic ) (b) ? (Diluted ) 17 7 64 7 44 15 08 15.06 4.33 3.31 3 87 7.62 7 43 432 3.31 387 #Figures are below Rs 0.01 Million ,hence disclosed as Rs .0.00
Page 6
Advanced Enzyme Technologies Limited CIN No.: L24200MH1989PLC051018 Regd. Office and Corporate Office: Sun Magnetica. 5th Floor, Near LIC Service Road. Louiswadi. Thane-400604. Maharashtra. India. Tel No:91-22-41703220 Fax No: +91-22-25835159 Website: www.advancedenzymes.com. Email Id :sanjay@advancedenzymes.com Statement of consolidated assets and liabilities (T in million) As at 31 March 2026 As at 30 September 2026Particulars AuditedUnaudited ASSETSI. (1) Non-current assets (a) Property, Plant and Equipment (b) Capital work-in-progress (c) Goodwill (d) Other Intangible assets (e) Intangible assets under development (f) Financial Assets (i) Investments (ii) Loans (ii) Other financial assets (g) Deferred tax assets (net) (h) Income tax assets (net) (i) Other non-current assets 2.758.32 511.69 3.694.60 469.22 3.076.90 832.16 3.739.39 427.95 0.01 0.649.47 0.961.18 96.84 48.78 230.33 140.49 119.77 69.12 242.05 112.78 7,951.878,630.78Total non-current assets (2) Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Other financial assets (c) Other current assets 1.772.772,027.11 5.838.30 1.450.20 1,087.55 71.76 4.873.27 1.380.25 1.587.63 266.00 3.11 2.43 75.42 213.76 86.25 126.46 10,426.55 10,435.74Total current assets Total assets 19,057.33 18,387.61 II. EQUITY AND LIABILITIES (1) Equity (a) Equity share capital (b) Other equity Equity attributable to the owners of the Company Non-controlling interest Total equity 220.53 16,427.38 223.85 16,095.72 16,647.91 551.04 16,319.57 511.65 17,198.95 16,831.22 (2) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liability (b) Provisions (c) Deferred tax liabilities (net) Total non-current liabilities 87.32 274 23 14.61 311.50 78.87 37 69 53.88 318.73 687.66 489.17 (3) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liability (iii) Trade payables a) total outstanding dues of micro enterprises and small enterprises b) total outstanding dues of creditors other than micro enterprises and small enterprises (iv) Other financial Liabilities (b) Other current liabilities (c) Provisions (d) Current tax liabilities (net) Total current liabilities 130.18 45.26 126.41 77.12 42.46 406.02 63.91 335.68 266.76 150.20 66.83 63.01 285.08 104.94 63.94 10.14 1,170.72 1,067.22 ITotal equity and liabilities 19,057.33 18,387.61
Page 7
Advanced Enzyme Technologies Limited CIN No. L24200MH1989PLC051018 Regd Office and Corporate Office Sun Magnetica. 5th Floor. Near LIC Service Road. Louiswadi. Thane-400604. Maharashtra. India Tel No:91-22-41703220 Fax No +91-22-25835159 Website: www advancedenzymes.com. Email Id sanjay@advancedenzymescom STATEMENT OF CONSOLIDATED CASHFLOW (fin million) For six months ended 30 September 2025 Unaudited For six months ended 30 September 2026 Unaudited A. Cash flows from operating activities Profit before tax 1144 411222.83 1144.411222.83 Adjustments for non-cash transactions Depreciation and amortization expense Prepaid lease amortisation (Profit)/Loss on sale of Property, plant and equipments Allowances for bad and doubtful trade receivables Bad and doubtful trade receivables wntten off Employee stock compensation expense Excess provision written back Sundry balances wntten (back)/ off (net) Fair valuation of investments in marketable securities Provision for inventory Unrealized foreign exchange (gain) / loss 207 75 196 94 0090 09 1.63(0 19) (0 02) (4 53) 1.660 08 29.0716.60 0 05(5.11) (0 09) (49 84) 0 02 (82.35) 5914 50 0.05 (8.05) 1,284.851,396.65 Items considered separately Interest income Interest expenses Operating profit before working capital changes Adjustments for: (Increase) / Decrease in non-current loans (Increase) / Decrease in other non-current financial assets (Increase) / Decrease in other non-current assets (Increase) / Decrease in inventories (Increase) / Decrease in trade receivables (Increase) / Decrease in Current loans (Increase) / Decrease in Other current financial assets (Increase) / Decrease in Other current assets (Decrease) / Increase in provisions (Decrease) / Increase in trade payables (Decrease) / Increase in Current financial liabilities- others (Decrease) / Increase in other current liabilities Cash generated from operating activities Income taxes paid (net of refund) Net cash generated from operating activities Cash flows from investing activities Purchase of property, plant and equipment Proceeds from sale of property, plant and equipments Purchase of intangible assets Purchase of non-current investments (Purchase) / Proceeds from sale of current investments (net) Interest received (Increase) in bank deposits with maturity more than 3 months but less than 12 months (Increase) / Decrease in bank deposits with maturity of more than 12 months Net cash generated/(used in) investing activities (102.11) 1761 (70.36) 14 83 1,312.15 1,229.32 (0.37) (187) (9.85) (251 68) 72 86 1 75 001 0 31 (141 66) (76 55) (1.83) (46.86) (41 69) (11 59) 111 09 (0.69) 8 95 (7997) (37 72) 47 40 (4.00) 19 10 (5.24) 28 75 1082.72 1037.40 (310.74) (390 27) 771.98 647.13 B. (516 05) (183.38) 0.32 2.77 (2 1 1) (8.82) 1103.60 80 28 (194.09) (20 60) (1.69) (240.42) 65.16 (5 30) 55 60 (307.26]442.53 C. Cash flows from financing activities Proceeds from issue of share capital including securities premium Buy back of equity shares including expenses incurred for buy back of equity shares (RepaymentJ/proceeds from long-term borrowings (net) (Repayment)/proceeds from short-term borrowings (net) Interest paid Lease liability paid Dividends paid Net cash (used In) financing activities 1.87 7.21 (520.77) (4.89) (13.97) (13.84) (38.56) 7 71 4 53 (16.94) (44.31) (155.17) (58878) (723.08) (652,83) 491 43 1087.55 (312.96) 942.25 (5.72) Net (decrease) / increase in cash and cash equivalents (A+B+C) Cash and cash equivalents as at the beginning of the year Effect of exchange rate changes on cash and cash equivalents held 865 Cash and cash equivalents as at the end of the period 1.587.63 623.57 Composition of cash and cash equivalents Cash in hand (including cheques on hand) Balance with banks . Current account Fixed deposit account (with maturity less than 3 months) Liquid fund balance (with maturity less than 3 months) 1 19 0.98 d 269.50 34.80 1282 14 302.13 3 74 316.72 1,587.63 623.57
Page 8
n AdvancedEnzymeTechnologiesLimited CINNoL24200MH1989PLC051018 RegdOfficeandCorporateOfficeSunMagnetica5thFloor.NearLICServiceRoadLouiswadiThane-400604.MaharashtraIndia TelNo91-22-41703220FaxNo+91-22-25835159 Websitewwwadvancedenzymescom.EmailIdsanjay@advancedenzymescom Notes: (i)TheaboveunauditedconsolidatedfinancialresultsincludethefinancialresultsofAdvancedEnzymeTechnologiesLimited(the"Company”orthe“HoldingCompany")andthefinancialresultsofthesubsidiarycompanies AdvancedBio-AgroTechLimited(India).AdvancedEnzytechSolutionsLimited(India).JCBiotechPrivateLimited(India),SatechSpecialitiesPnvateLimited(India)SaiganeshEnzyte^ iSolutionsPrivateLimited(India) AdvancedNutrazymePrivateLimited(lndia)(wef4July2025)AdvancedEnzymesUSA.Inc(USA).CalIndiaFoodsInternational(USA).AdvancedSupplementaryTechnokgiesCorporation(USA).Enzyme Innovation.Inc(USA).StaryaLabs.Inc(USA).AdvancedEnzymesEuropeBV(Netherlands)EvoxxTechnologiesGmbH(Germany)andanassociateRaywattSolarEnviroPrivateLimited(wef10August2026)The HoldingCompany,itssubsidiaryconstitutethe“Group* (ii)TheaboveunauditedconsolidatedfinancialresultsoftheGroupanditsassociatewerereviewedbytheAuditCommitteeandthereafterapprovedbytheBoardofDirectorsattheirHirelingheldon31October2026The aboveresultshovebeenreviewedbythestatutoryauditorsoftheCompanyandtheyhaveexpressedanunmodifiedconclusionThereviewreportwillbefiledwithstockexchangesarilwillbeavailableontheCompanys websiteTheaboveresultshasbeenpreparedinaccordancewiththeCompanies(IndunAccountingStandards)Rules2015(IndAS)prescnbedunderSection133oftheComparesAct2013andotherrecognised accountingpracticesandpoliciestotheextentapplicable (HI)TheGroupoperatesonlyinonebusinesssegmentvizmanufacturingandsalesofenzymes’ (iv)TheBoardofDirectorsinitsmeetingheldon9May2026hadproposedthefinaldividendforthefinancialyear2025-26ofRs135/-perequityshareandthesamehasbeenapprover:bytheshareholdersoftheCompany initsAnnualGeneralMeetingheklon31July2026ondpadon5August2026 (v)TheCompanytiasincorporatedanewwhotyownedsubsidiarybynameofAdvancedNutrazymePrivateLimited(’ANPL*)thesubsidiaryreceiveditscertificateofincorporationon4Juy2025ANPLwinbeengagednthe businessofsalesanddistnbutionoftheCompany’sNutritionandWellnessrangeofproducts (vt)TheBoardofDirectorsatitsmeetingheldon8August2026hadapprovedthebuybackoffullypaidupequitysharesoffacevalueofRs2eachfromtheeligibleequitysharehodersoftheCompanyotherthanthe Promoters,thePromotergroupandPersonswhoareincontroloftheCompany,atapricenotexceedingRs500perequityshare(MaximumBuybackPrice)payableincashforanaggregateamountnotexceedingRs 69700million(MaximumBuy-backSize,excludingtransactioncostsandtaxesthereon)fromfheOpenMarketroutethroughthestockexchangemechanismundertheCompaniesAd2013andSecuntiesandExchange BoardofIndia(Buy-backofSecurities)Regulations.2018asamended(Buy-backRegulations') AttheMaximumBuy-backPriceofRs500andtheMaximumBuy-backSizeofRs697million,theindicativemaximumnumberofequitysharestobeboughtbackis1394000equityshansrepicsentmgapproximately124% ofthetotalpaid-upcapitalThemaximumbuybacksizerepresents999%and509%oftheaggregateofthetotalpaid-upequitysharecapitalandfreereservesoftheCompanytasedontheauditedstandaloneand consolidatedfinancialstatementsoftheCompanyasat31March2026respectively,whichisnotmorethan10%ofthetotalpaid-upcapitalandfreereservesoftheCompanymaccordancewiththeprovisototheRegulation 5(i)(b)oftheBuy-backRegulations TheBuy-backcommencedon14August2026andasof30September2026theschemeofBuybackisopenTheCompanyboughtback1.713324equitysharesasof30September20&resultingintotalcashconsideration ofRs52077million(includingRs8/8milliontowardsbuybackrelatedexpensesandtransactioncostonBuy-back)Outofthetotalequitysharesbroughtback825.028equityshareswreextinguishedon7September2026 aspertherecordsofthedepositoriesTheremairwig8.88296equitysharesweresubsequentlyextinguishedon7October2026aspertherecordsofthedepositoriesThesubsequenteitinguishmenthasbeenconsideredas anadjustingeventmaccordancewithIndAS10."EventsaftertheReportingPenod'astheunderlyingshareswerealreadyboughtbackasatthereportingdateandonlytheformalprocessofextinguishmentwaspending AccordinglytheentirebuybackhasbeenaccountedforinthefinancialresultsforthequarterandsixmonthendedSeptember30.2026 AspertherequirementsoftheCompaniesAct2013anamountofRs51734millionhasbeenutilisedfromsecuntiespremiumaccountforthebuybackrepresentingtheexcessofbuybackconsiderationoverthefacevalueof equitysharesandtransactioncostsFurther,capitalredemptionreserveofRs343miMionrepresentingthenominalvalueofsharesboughtbackhasbeencreatedthroughappropriationfomsurplusinthestatementofProfit& LossinaccordancewithSection69oftheCompaniesAct.2013 Asat30October2026theCompanyboughtback2.410.906equitysharesfromtheopenmarketutilisingRs69696million(excludingtransactioncosts)representing9999%utitsationoftheapprovedbuybacksue Accordingly,theBuybackCommittee,initsmeetingheldon30Octobor2026approvedtheclosureofthebuybackprogrammeTheequitysharesbroughtbackduringOctober2026wifl:eextinguishedinaccordancewiththe applicableprovisionsoftheCompaniesAct.2013 (VN)On21November2025.theGovernmentofIndianotifiedthefourLabourCodes-theCodeonWages.2019theIndustrialRelationsCode.2020.theCodeonSocialSecurity202C.andtheOccupationalSafety.Health andWorkingConditionsCode.2020-consolidating29existinglabourlawsTheMinistryofLabour&EmploymentpublisheddraftCentralRulesandFrequentlyAskedQuestions(FAQstoenabioassessmentofthefinancial impactduetochangesmregulations TheGrouphadassessedanddisclosedtheincrementalimpactotthesechangesonthebasisofcurrentremunerationstructureBasedonourassessmentandtheinformationavailableconsistentwiththeguidanceprovided bytheInstituteofCharteredAccountantsofIndiaandconsideringthematenaWyandregulatory-drivennon-recurringnatureofthisimpacttheGrouppresentedsuchincrementalmpactunder“ExceptionalItems'mthe consolidatedfinancialresultsfortheyearended31March2026TheincrementalimpactconsistingofgratuityofRs4630millionandcompensatedabsencesofRs151millionpmanlyaroseduetochangemwage definition (vm)On22August2025UnitedStatescourtofappealshaddirectedtheDistrictofAnzonatopasstheorderinfavourofAdvancedSupplementaryTechnologiesCorporation(U S A)("AST”)whollyownedsubsidiaryof AdvancedEnzymeUSAInc(USA)forthelawsuitfiledbytheCompetitorBasedontheabovedirectionofUnitedStatesCourtofAppealsandlegalopinionreceivedinthequarterended31December2025theprovision createdearlierwithrespecttothementionedlawsuitwasreversedTheGrouppresentedsuchimpactunderExceptionalItems'intheconso’idatedfinancialresuttsfortheyearended3'March2026Theimpactpertainingto theabovementionedlawsuitwasRs16139million ByOrderoftheBoarddDirectors ForAdvancedEnzymeTechnologiesLimited CINNOL24200MH19SPLC051018 M.M.Kabra WholetimeDirector DIN00148294 PlaceNastuk Dated31October2026
Page 9
MSK A fit Associates LLP HO 602, Floor 6, Raheja Titanium Western Express Highway, Geetanjali Railway Colony, Ram Nagar, Goregaon (E) Mumbai 400063, INDIA Tel: +91 22 6974 0200 (Formerly known as M S K A & Associates) Chartered Accountants Independent Auditor’s Review Report on Standalone unaudited financial results of Advanced Enzyme Technologies Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Advanced Enzyme Technologies Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as ‘the Company’) for the quarter ended September 30, 2026 and the year to-date results for the period from April 01, 2026 to September 30, 2026 (‘the Statement’) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Company’s Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For M S K A & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants ICAI Firm Registration NO.105047W/W101187 Virendra Kanak Partner < Membership No.: 110811 * uDiN24i\«uxjjnr ^Place: Mumbai Date: October 31, 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN:ACT-3789 Ahmedabad I Bengaluru | Chandigarh I Chennai I Coimbatore I Goa | Gurugram I Hyderabad | Kochi | Kolkata Pune www.mska.in
Page 10
Advanced Enzyme Technologies Limited C1N No.. L24200MH1989PLC051018 Regd Office and Corporate Office Sun Magnetien, 5th Floor, Near LIC Service Road, Louiswadi,Thane-400604, Maharashtra, India. Tel No:91-22-41703220 Fax No: +91-22-25835159 Website: tvww advancedenzyntes.com.Email Id :sanjay@advancedcnzymes.com t Statement of Unaudited standalone financial results for the quarter and six months ended 30 September 2026 IRS in Million extent per share data) Year endedSix months endedQuarter ended 3l-Mar-26 Audited 30-Sep-25 Unaudited 30-Sep-26 Unuudited 30-Sep-25 Unaudited 30-Jun-2630-Scp-26 Unaudited Particulars Unaudited \ 2,530.25 186.84 2.407.72 569,31 4.527.66 633.88 1.158.57 1.157.48Revenue from operations Other Income 1371.68 163.97 I 22.87 30.792 5,161.542,977.031,535.65 1,181.44 1,188.27 2,717,093 Total Income ( 1+2) Expenses (a) Cost of materials consumed ( b) Changes in inventories of finished goods and work-in-progress (ct Employee benefits expense (d) Finance costs (including exchange difference) (c) Depreciation and amortisation expense ( IT Other expenses 4 566.02 (12.65) 157.92 480.94 483.24 1,046.96 (77.69) 334.85 1.002.23 1,877 21 (30.82) 647 28 (65.04) 176.93 (22.73) 160.62 20.83 322.69 2.070.31 0.37 0.68 1.020.49 31.73 281 20 60.94 542 82 59.3129.21 30.02 240.44 120.83 929.65460.80261 62 t otal expenses 1,024.53 884.03 892.08 1,866.88 3,546,221,908.56 5 Prufit befure exceptional item and tax (3-4) 6 Exceptional item (refer note iv) 511.12 297,41 2%.19 808.53 1,110.15 1,615.32 38 58 Profit before tax (5-6) Tax expense Current tax 808.53 1,110.15 1,576.747 511.12 297.41 296.19 8 92.82 66 64 72.83 159.46 147.24 270 69 Deferred lax clmritc/(crcdit) 1.25 7.31 0.54 8.56 028 ( 12.01 ) Total tax expense 94.07 73.95 73.37 168.02 258.68147.52 Net profit for the period (7-8)9 417.05 223,46 222.82 1,318.06640.51 962,63 Other comprehensive income A (i) Items that will not be reclassified to Profit or Loss 10 Rcnicasurements of defined benefit liability/(asscl) ( li) Income tax related to items that will not be reclassified to Profit or Loss Bdl Items that will be reclassified to Profit or Loss Hi ) Income tax related to items that will be reclassified to Profit or Loss Total Other comprehensive income 11.27 ( 284) 8.43 Total comprehensive income (9+10)I I 417.05 223.46 222.82 640,51 962.63 1,326.49 12 Paid-up Equity Share Capital (Face Value ? 2 each fully paid up) ( refer note v) Other equity 220.53 223.95 223.76 220.53 223.76 223.85 6,872.3813 Burnings Ter Share of * 2 each ( not annualized) (a) ? ( Basic) (b) t ( Diluted) 14 3.74 2.00 1.99 5.73 8.60 11.78 3.73 I 99 199 5.72 8.59 11.76
Page 11
* Advanced Enzyme Technologies Limited CIN No.:L24200MHI989PLC05I0I 8 Regd.Office and Corporate Office:Sun Magnctica,5th Floor, Near LIC Service Rond, Louistvadi, Thane-400604, Maharashtra, India. Tel No:91-22-41703220 Fax No:+91-22-25835150 Website:www.advaneedenzymes.com, Email Id :sanjay@advanccdcnzymcs.eom Statement of standalone assets and liabilities ( f i nmillion) As at 31 March 26 As at 30 Sep 26Particulars Unaudited Audited I. ASSETS (I ) Non-current assets (a) Property. Plant and Equipment (b) Capital work-in-progress (c) Other Intangible assets (d) Intangible assets under development # (e) Financial Assets (i) Investments - Investment in subsidiaries -other investment 1.544.08 824.31 49.95 1.454 65 486.89 51.24 0.01 0.00 2.542.812,547.48 0.62 0.62 0.96(li) Loans (iii) Other Financial assets (f) Income tax asset (net) (g) Other non-current assets Total non-current assets I 18 67.47 166.46 33.24 45.01 165.86 128.53 5,234.80 4,876.57 (2) Current Assets (a) Inventories (b) Financial Assets (l) Investments (ill Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Other financial assets (c) Other current assets Total current assets 1,272.85 1.165 16 146 30 956.79 38.87 197.38 910.58 943.23 18.04 4.51 1.28 1.47 51.23 62 15 110.60 53.75 2,775,30 3.159.79 Total assets 8.010.10 8,036,36 II. EQUITY AND LIABILITIES (I) Equity (a) Equity share capital (b) Other equity Total equity 220.53 6,86266 223.85 6,87238 7,083,19 7,096.23 (2) Non-current liabilities (a) Financial liabilities (i) Lease liability (b) Provisions (c) Deferred tax liabilities (net) Tutnl nun-current liabilities 8 53 10.33 42.55 108.831 ) 7.39 161.71125,92 (3) Current liabilities (a) Financial liabilities (i) Lease liability (ii) Trade payables a) total outstanding dues of micro enterprises and small enterprises b) total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial Liabilities (b) Other current liabilities (c) Provisions (d) Current tax liabilities (net) Total current liabilities 6 52 S> 17 20.39 439 51 47.23 464.67 149.38 161 92 54.8489 58 50.67 44.94 37.67 2.92 800.99 778,42 Total equity and liabilities 8.010,10 8,036.36 # Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00 i
Page 12
Advanced Enzyme Technologies Limited CIN No L24200MH1989PLC051018 Regd. Office and Corporate Office:Sun Magnctica, 5th Floor, Near L1C Service Road.Louiswadi, Thane-400604, Maharashtra, India.Tel No 91-22-41703220 Fax No:+91-22-25835159 Website, www.advancedenzynies.com.Email Id .sanjay@advancedcnzymcs.com STATEMENT OF STANDALONE CASH FLOW For six months ended 30 September 2025 Rs. in million Unaudited For six months ended 30 September 2026 Rs.in million Unaudited Cash flows from operating activities Profit before tax A. 1,110.15808.53 1.110.15808.53 Adjustments for non-cash transactions Depreciation and amortization expense (Profit) / Loss on sale of properly, plain and equipment (acl) Bad debts written off Provision for doubtful trade receivables provided / (written back) Employee stock compensation expense Excess provision written back Sundry balances written of)'/ ( back) ( net ) Unrealized foreign exchange Loss/(gain) Fair value adjustment on investments «0.94 5931 0.19(0.27) 0.100.07 (538) 25.2514.43 0.050.00 0.02(0.09) (8.08) ( 28 15) 0.05 (12.21) 1,153 46871.45Items considered separately Interest income Interest expenses Dividend income Operating prollt before working capital changes Adjustments for working capital changes. ( Increase ) / Decrease in Ollier non-current financial assets (Increase) / Decrease in oilier non-currenl assets ( Increase) / Decrease in inventories (Increase) / Decrease in trade receivables (Increase) / Decrease in Currenl loans ( incieasc) / Decrease in other current financial assets I Increase) / Decrease in Ollier current assets ( Decrease ) / Increase in provisions (Decrease) / Increase ill trade payables ( Decrease) / Increase in other current financial liabilities (Decrease!/ Increase in oilier current liabilities Cash generated from upd ating activities (4.04)(3.48) 1.020.68 (535.41)(155.92) 615.03712.73 001(1.87) 1.060.59 (11.58) (229.71) (1.28) (59.25) (31.06) (3.76) 148.43 (107.69) (13.33) 0.19 8.14 (56.85) (29.55) (52.25) (7.36) 34.74 II 55 35 22 474 66487.49 Income taxes paid ( net! (167.14)(118.02) Net cash generated from operating activities 307,52369.47 B. Cash flows from investing activities Purchase of property, plant and equipment (tangible assets| Proceeds from sale of property, plant and equipment Purchase of intangible assets Purchase of non-currenl investments (Purchase) / Proceeds from sale of current investments ( net ) Interest received Dividend received ( Increase) / Decrease in bank deposits with inability more than 3 months but less Ilian 12 months(Increase) / Decrease in bank deposils with maturity of more than 12 monthsNet cash generated in investing activities (395.21) ( 138.33) 0.140.27 (2.11) (2.50) 776.48 (1.69) (0.50) ( 158 07) 6.03 1.11 535.41 (3.23) 55,60 155.92 (192.63) (20.60) 325.65 290.44 C. Cash flows from financing activities Proceeds from issue of share capital including securities premiumBuy back of equity shares including expenses incurred for buy back of equity sharesInterest p;tul i> Payment of Lease liabilities Dividends paid Net cash (used in) financing activities 1.87 7.21 (520.771 (0.00) (5.12) (151.17) (0.00) (4.88) (581.78) (675.19) (579.45) Net (decrease) / increase in cash and cash equivalents ( A+B+C)Cash aixl cash equivalents as at the beginning of the period 19.93 18.51 18.94 56.04 Cush and cash equivalents as at the end of the period 38,87 74.55 Composition of cash and cash equivalents Cash in hand including cheques on hand Balance with banks Current account Fixed deposit account ( with maturity less than 3 months) 0.86 0.50 34.66 70.83 3.223,35 38.87 74,554 Figures are below Rs 0.01 Million, lienee disclosed as Rs 0.00 d
Page 13
Advanced Enzyme Technologies Limited CINNo L24200MH1989PLC051018 Regd. Office and Corporate Office Sun Magnetica, 5th Floor. Near LIC Service Road, Louiswadi.Thane-400604. Maharashtra, India. Tel No:91-22-41703220 Fax No: +91-22-25835159 Website www.advancedenzymes.com.Email Id :sanjay@advancedenzymes.com Notes; ( t ) The above unaudited standalone financial results of Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 31 October 2026. The above results have been subjected to ‘Limited Review' by the statutory auditors of the Company and they have expressed an unmodified conclusion. The limited review report will be filed with slock exchanges and will be available on the Company's website. The above results have been prepared in accordance with the Companies ( Indian Accounting Standards) Rules. 2015 ( Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India. (li) The Company operates only in one business segment viz. manufacturing and sales of enzymes' (lii) The final dividend for the financial year 2025-26 of Rs 1.35/- per equity share is paid on 5 August 2026 after approval of the shareholders of the Company in its Annual General Meeting held on 31 July 2026 (tv) On 21 November 2025. the Government of India notified the four Labour Codes-the Code on Wages, 2019.the Industrial Relations Code, 2020.the Code on Social Security. 2020.and the Occupational Safety. Health and Working Conditions Code, 2020 -consolidating 29 existing labour laws. The Ministry of Labour & Employment published dralt Central Rules and Frequently Asked Questions (FAQs) to enable assessment of the financial impact due to changes in regulations. The Company had assessed and disclosed the incremental impact of these changes on the basis of current remuneration structure. Based on our assessment and the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India and considering the materiality and regulatory- driven. non-recurring nature ol this impact, the Company presented such incremental impact under “Exceptional Items'' in the standalone financial results for the year ended 31 March 2026 The incremental impact consisting of gratuity of Rs.38 58 million primarily arose due to change in wage definition (v ) The Board of Directors at its meeting held on 8 August 2026 had approved the buy-back of fully paid up equity shares of face value of Rs 2 each from the eligible equity shareholders of the Company other than the Promoters, the Promoter group and Persons who are in control of the Company, at a price not exceeding Rs. 500 per equity share (Maximum Buy-back Price), payable in cash for an aggregate amount not exceeding Rs 697.00 million (Maximum Buy-back Size, excluding transaction costs and taxes thereon), from the Open Market route through the stock exchange mechanism under the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018,as amended ('Buy-back Regulations'). At the Maximum Buy-back Price of Rs 500 and the Maximum Buy-back Size of Rs 697 million, the indicative maximum number of equity shares to be bought back is 1.394,000 equity shares, representing approximately I 24° O of the total paid-up capital The maximum buy back size represents 9 99% and 5.09*/.of the aggregate of the total paid-up equity share capital and free reserves of the Company based on the audited standalone and consolidated financial statements of the Company as at 31 March 2026 respectively, which is not more than 10% of the total paid-up capital and free reserves of the Company in accordance with the proviso to the Regulation 5(iXb) of the Buy-back Regulations. The Buy-back commenced on 14 August 2026 and as of 30 September 2026, the scheme of Buyback isopen. The Company bought back 1.713,324 equity shares as of 30 September 2026 resulting in total cash consideration of Rs 520.77 million ( including Rs 8 78 million towards buy back related expenses and transaction cost on Buy-back). Out of the total equity shares brought back 825,028 equity shares were extinguished on 7 September 2026 as per the records of the depositories. The remaining 888.296 equity shares were subsequently extinguished on 7 October 2026 as per the records of the depositories. The subsequent extinguishment has been considered as an adjusting event in accordance with Ind AS 10."Events after the Reporting Period", as the underlying shares were already bought back as at the reporting dale and only the formal process of extinguishment was pending. Accordingly, the entire buyback has been accounted for in the financial results for the quarter and six month ended September 30, 2026. As per the requirements of the Companies Act. 2013 an amount of Rs 517.34 million has been utilised from securities premium account for the buyback representing the excess of buyback consideration over the face value of equity shares and transaction costs Further, capital redemption reserve of Rs 3.43 million representing the nominal value of shares bought back has been created through appropriation from surplus in the statement of Profit & Loss in accordance with Section 69 of the Companies Act.2013 As at 30 October 2026. the Company bought back 2,410,906 equity shares from the open market utilising Rs 696.96 million (excluding transaction costs), representing 99 99% utilisation of the approved buyback size. Accordingly, the Buyback Committee, in its meeting held on 30 October 2026, approved the closure of the buyback programme The equity shares brought back during October 2026 will be extinguished in accordance with the applicable provisions of the Companies Act, 2013. By Order of the Board of Directors For Advanced Enzyme Technologies Limited C1N: L24200MH1989PLC051018 ML M.Kabra " * Wholetimc Director DIN : 00148294 Place Nashik Dated: 31 October 2026 <z
Page 14
Annexure II - The details of the promoter group members who had requested for reclassification along with the views of the Board. The Board of Directors of the Company (“Board”) have analysed the reclassification requests as received by the Company from the following Promoter Group Members: Sr. No. Name of the Promoter Group Members Existing Category Number of Equity Shares % of total Shareholding 1. Savita Chandrakumar Rathi Promoter Group Nil Nil 2. Piyush Chandrakumar Rathi Promoter Group Nil Nil 3. Radhika Ashish Pujara Promoter Group Nil Nil 4. Atharva Green Ecotech LLP Promoter Group Nil Nil 5. Advenza Global Limited Promoter Group Nil Nil 6. Jayesh Madhusudan Soni Promoter Group 10,000 0.01 7. Shruti Sharad Dhamdhere Promoter Group 10,000 0.01 8. Dhanyakumar Kishor Gadiya Promoter Group 5,000 0.00 9. Pratik Prakash Kokane Promoter Group 10,000 0.01 10. Snehal Shamsunder Soni Promoter Group 15,000 0.01 11. Payal Akshay Kulkarni Promoter Group Nil Nil 12. Sunil Ramdayal Attal Promoter Group 1,000 0.00 13. Megha Jhawar Promoter Group 8,000 0.01 Total 59,000 0.05 The views of the Board on the reclassification request received are as follows: (i) As per the provisions of Regulation 31A of the SEBI Listing Regulations, the term “promoter(s) seeking re-classification” shall mean all such promoters/persons belonging to the promoter group seeking re-classification of status as public. Pursuant to the provisions of Regulation 31A (1)(b) of SEBI Listing Regulations “persons related to the promoter(s) seeking re-classification” shall mean such persons with respect to that promoter(s) seeking re-classification who fall under sub-clauses (ii), (iii) and (iv) of ^ UvancGd enzymesWhere ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200,Fax: +91-22-2583 5159 Email:info@advancedenzymes.com, www.advancedenzymes.com Factory :Plot No. A-61/62, MIDC Malegaon, Tal. Sinnar, Dist. Nashik - 422 113. Maharashtra. India. Tel.: +91-99701 00750 / +91-2551-230 044, Fax: +91-2551-230 816
Page 15
clause (pp) of sub-regulation (1) of Regulation 2 of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ SEBI ICDR Regulations”). (ii) Mrs. Savita Chandrakumar Rathi, a Promoter Group Member seeking reclassification, has provided the list of her related persons in terms of Regulation 2(1)(pp)(ii) and (iv) of the SEBI ICDR Regulations; relevant details of her related persons are set out below: Name Relation with Mrs. Savita Rathi Category No. of Equity Shares Percentage (%)* Chandrakumar Rathi Spouse Promoter Nil Nil Piyush Chandrakumar Rathi Son Promoter Group Member Nil Nil Radhika Ashish Pujara Daughter Promoter Group Member Nil Nil Advenza Global Limited Body Corporate in which twenty percent or more of the equity share capital is held by Mrs. Rathi and/or immediate relative of her Promoter Group Member Nil Nil Atharva Green Ecotech LLP Promoter Group Member Nil Nil Vasant Rathi Brother of Spouse Promoter 2,98,71,702 26.87 Kishor Rathi Brother of Spouse Promoter Group 4,06,000 0.37 Kishor Rathi HUF Kishor Rathi Karta of Kishor Rathi HUF Promoter Group 11,00,000 0.99 Total 3,13,77,702 28.23 * The above percentage has been calculated on the basis of the Company's paid-up equity share capital as on September 30, 2026, comprising 11,11,51,122 equity shares of face value ₹2 each. (iii) In view of the above, Mrs. Savita Chandrakumar Rathi, a Promoter Group Member seeking reclassification as a Public Shareholder, together with her related persons, as detailed above, holds more than ten percent of the voting rights in the Company. Accordingly, as per the Board’s view, the conditions prescribed under Regulation 31A(3)(b) of the SEBI Listing Regulations are not met. ^ UvancGd enzymesWhere ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200,Fax: +91-22-2583 5159 Email:info@advancedenzymes.com, www.advancedenzymes.com Factory :Plot No. A-61/62, MIDC Malegaon, Tal. Sinnar, Dist. Nashik - 422 113. Maharashtra. India. Tel.: +91-99701 00750 / +91-2551-230 044, Fax: +91-2551-230 816
Page 16
(iv) Other immediate relatives of Mrs. Savita Chandrakumar Rathi, in respect of whom the Company has received requests for reclassification are Mr. Piyush Chandrakumar Rathi, Mrs. Radhika Ashish Pujara, Advenza Global Limited and Atharva Green Ecotech LLP (hereinafter collectively referred to as the “Promoter Group I”). (v) Of the said Promoter Group I, Mr. Piyush Chandrakumar Rathi and Mrs. Radhika Ashish Pujara are related to Mr. Chandrakumar Rathi (Promoter) and Mrs. Savita Chandrakumar Rathi (Promoter Group Member) as their son and daughter, respectively, and are considered as immediate relatives for the purposes of Regulation 2(1)(pp)(ii) of the SEBI ICDR Regulations. (vi) Further, Advenza Global Limited and Atharva Green Ecotech LLP are the body corporates referred to in Regulation 2(1)(pp)(iv)(a) of the SEBI ICDR Regulations, in which twenty percent or more of the equity share capital is held by the Promoter, Mr. Chandrakumar Rathi and his immediate relatives who have submitted the request for reclassification i.e. Mrs. Savita Chandrakumar Rathi, Mr. Piyush Chandrakumar Rathi and Mrs. Radhika Ashish Pujara and the name of the said body corporates are disclosed by the said three individual Promoter group members in their respective list of related persons. In view of the above, the conditions prescribed under Regulation 31A(3)(b) read with Regulation 31A(1) of the SEBI Listing Regulations are not met for the said Promoter Group I. (vii) Considering the aforesaid, the Board was of the view that the reclassification requests submitted by Mrs. Savita Chandrakumar Rathi, Mr. Piyush Chandrakumar Rathi, Mrs. Radhika Ashish Pujara, Advenza Global Limited and Atharva Green Ecotech LLP do not satisfy the conditions stipulated under Regulation 31A(3)(b) read with Regulation 31A(1) of the SEBI Listing Regulations. (viii) As regards the remaining Promoter Group members who have applied for reclassification i.e. Mr. Jayesh Madhusudan Soni, Mrs. Shruti Sharad Dhamdhere, Mr. Dhanyakumar Kishor Gadiya, Mr. Pratik Prakash Kokane, Mrs. Snehal Shamsunder Soni, Mrs. Payal Akshay Kulkarni, Mr. Sunil Ramdayal Attal and Mrs. Megha Jhawar (“hereinafter referred to as “ Promoter Group II ”) became members of the Promoter Group due to earlier gift of equity shares from the Promoter Group Members over the past few years, pursuant to in accordance with Regulation 31A(6) of the SEBI Listing Regulations. (ix) Promoter Group II has provided their respective list of related persons in terms of Regulation 2(1)(pp)(ii) and (iv) of the SEBI ICDR Regulations. Considering the above and said list, the said Promoter Group II together with their related persons, as defined therein, meet the conditions set out in Regulation 31A(3)(b) read with Regulation 31A(1) of the SEBI Listing Regulations and also the said Promoter Group II do not hold more than one percent of the total voting rights in the Company and accordingly, the Advanced enzymesWhere ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200,Fax: +91-22-2583 5159 Email:info@advancedenzymes.com, www.advancedenzymes.com Factory :Plot No. A-61/62, MIDC Malegaon, Tal. Sinnar, Dist. Nashik - 422 113. Maharashtra. India. Tel.: +91-99701 00750 / +91-2551-230 044, Fax: +91-2551-230 816
Page 17
approval of the shareholders of the Company in a general meeting is not required in terms of Regulation 31A(3)(a)(iv)(a) of the SEBI Listing Regulations. (x) Sub-regulation (3)(a)(ii) of Regulation 31A of the SEBI Listing Regulations provides that the Board of Directors of a listed entity shall analyze the request for reclassification, provide their views and submit an application to the recognized stock exchanges seeking their no-objection / approval. Accordingly, the Board of Directors of the Company considered and analyzed the aforesaid reclassification requests, as detailed hereinabove, and decided to submit an application to BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”), seeking their no-objection / approval for the proposed reclassification, together with the Board’s views thereon and the requisite documents in accordance with the respective checklists prescribed by the Stock Exchanges. (xi) The reclassification requests as mentioned above shall be subject to the receipt of no-objection / approval of the Stock Exchange(s) as mentioned under the provisions of Regulation 31A of SEBI Listing Regulations. Advanced enzymesWhere ENZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India Tel: +91-22-4170 3200,Fax: +91-22-2583 5159 Email:info@advancedenzymes.com, www.advancedenzymes.com Factory :Plot No. A-61/62, MIDC Malegaon, Tal. Sinnar, Dist. Nashik - 422 113. Maharashtra. India. Tel.: +91-99701 00750 / +91-2551-230 044, Fax: +91-2551-230 816